MAPK/ERK pathway
From Proteopedia
(Difference between revisions)
Line 49: | Line 49: | ||
Genes whose transcription is regulated by CREB include: ''c-fos'', BDNF, [[tyrosine hydroxylase]], numerous [[neuropeptides]] (such as somatostatin, [[enkephalin]], VGF, corticotropin-releasing hormone), and genes involved in the mammalian [[circadian clock]] ([[PER1]], [[PER2]]). | Genes whose transcription is regulated by CREB include: ''c-fos'', BDNF, [[tyrosine hydroxylase]], numerous [[neuropeptides]] (such as somatostatin, [[enkephalin]], VGF, corticotropin-releasing hormone), and genes involved in the mammalian [[circadian clock]] ([[PER1]], [[PER2]]). | ||
+ | ==Clinical significance== | ||
+ | ===The first drug licensed to act on this pathway is [[sorafenib]] — a Raf kinase inhibitor=== | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> |
Revision as of 11:56, 21 February 2022
|
References
- ↑ Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002 Dec 1;62(23):6997-7000. PMID:12460918
- ↑ Antony R, Emery CM, Sawyer AM, Garraway LA. C-RAF mutations confer resistance to RAF inhibitors. Cancer Res. 2013 Aug 1;73(15):4840-51. doi: 10.1158/0008-5472.CAN-12-4089. Epub, 2013 Jun 4. PMID:23737487 doi:http://dx.doi.org/10.1158/0008-5472.CAN-12-4089